Precigen, Inc. (PGEN) company profile
Close on Nov 17, 2026Market cap $1.54BP/E –Yield –
About Precigen
Pharmaceutical Preparations, SIC 2834
Precigen is a commercial-stage biopharmaceutical company focused on precision medicines for immuno-oncology, autoimmune disorders, and infectious diseases. Utilizing platforms such as AdenoVerse, UltraVector, and UltraCAR-T, the company engineers gene programs and therapies targeting intractable conditions. Its first commercial product is Papzimeos, an adenoviral vector-based immunotherapy approved for treating adult recurrent respiratory papillomatosis. Precigen also maintains an investigational pipeline that includes PRGN-2009 for human papillomavirus-associated malignancies and PRGN-3006 for acute myeloid leukemia. Its offerings serve adult patients, healthcare providers, and integrated delivery networks managing rare diseases and oncology indications.
The company operates internal current good manufacturing practices facilities in Germantown, Maryland, to support drug substance manufacturing and commercial supply. Precigen distributes its approved therapy nationwide across the United States through hospital systems, community clinics, and integrated delivery networks. Additionally, the company seeks international expansion, having submitted a marketing application for European review. Precigen conducts clinical trials at partner institutions across the country and collaborates with entities including the National Cancer Institute.
Summary of the business section of Precigen's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Precigen, Inc.
- Founded
- 1998
- Headquarters
- Germantown, MD
- Address
- 20374 Seneca Meadows Parkway 20876
- Phone
- (301) 556-9900
- Website
- precigen.com
- Employees
- 20, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Virginia
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Baltimore, Maryland
Stock & identifiers
- Ticker
- PGEN
- Former tickers
- XON until Feb 4, 2020
- Exchange
- Nasdaq
- IPO date
- Aug 8, 2013
- Shares outstanding
- 358M, Jul 31, 2026
- Public float
- $219.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1356090
- CUSIP
- 46122T102
- ISIN
- US46122T1025
- FIGI
- BBG000QL8VH9
- Share class FIGI
- BBG001SSB3T5
- LEI
- 549300XCWNQU35K64G19
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Harry Thomasian Jr. | Chief Financial Officer | 311,911 |
| Donald P. Lehr | Chief Legal Officer | 758,181 |
| Phil Tennant | Chief Commercial Officer | 221,158 |
| Helen Sabzevari | President and CEO | 3,789,705 |
| Rutul R. Shah | Chief Operating Officer | 468,865 |
| Jeffrey B. Kindler | Director | 17,100 |
| Nancy H. Agee | Director | 309,187 |
| Randal J. Kirk | Director | 116,301,090 |
| Vinita D. Gupta | Director | 669,027 |
| Fred Hassan | Director | 1,243,239 |
| Cesar L. Alvarez | Director | 782,909 |
| Steven Frank | Director | 1,226,391 |
| James S. Turley | Director | 685,417 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $5.35M | $18.57M | $1.43M | $41 | $125 |
| FY2024 | $5.43M | $4.61M | $1.31M | $20 | $114 |
| FY2023 | $3.72M | $3.73M | $1.03M | $24 | $115 |
| FY2022 | $3.50M | -$1.09M | $892.36K | $28 | $111 |
| FY2021 | $2.52M | -$16.11M | $611.02K | $68 | $125 |
| FY2020 | $20.41M | $41.48M | $1.17M | $186 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Helen Sabzevari Chief Executive Officer | $1.00M | $2.22M | $1.07M | $1.05M | $20.13K | $5.35M | -1% |
| Harry Thomasian Jr. Chief Financial Officer | $488.00K | $464.97K | $374.22K | $131.76K | $35.76K | $1.49M | +7% |
| Donald P. Lehr Chief Legal Officer | $575.00K | $408.75K | $267.30K | $132.25K | $46.90K | $1.43M | +6% |
| Rutul Shah Chief Operating Officer | $485.00K | $499.90K | $384.91K | $145.50K | $45.60K | $1.56M | +11% |
| Phil Tennant Chief Commercial Officer | $510.00K | $271.10K | $267.30K | $137.70K | $43.85K | $1.23M | +137% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Aug 8, 2013
- Offer price
- $16.00
- Securities offered
- 9,999,999
- Gross proceeds
- $160.00M
- Exchange
- NYSE
- First trading day
- Aug 8, 2013
- First-day close
- $24.73+54.6%
- Lock-up ends (est.)
- Feb 4, 2014
“Per share Total Initial public offering price $ 16.00 $ 159,999,984 Underwriting discount s and commissions(1) $ 1.12 $ 11,199,999 Proceeds to us, before expenses $ 14.88 $ 148,799,985 (1) We refer you to “Underwriting” beginning on page 166 for additional information regarding total underwriting compensation.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, Exemplar had 20 employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?